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Observations From a
Transradial Registry
Our Remedies Oft in Ourselves Do Lie*
Sunil V. Rao, MD
Durham, North Carolina
Our remedies oft in ourselves do lie
Which we ascribe to heaven.
—Helena, in William Shakespeare’s
All’s Well That Ends Well (1)
Transradial coronary angiography and intervention has
long been considered a niche procedure; however, over the
past few years, the excitement around the radial approach
has been palpable. Whether it is increased exposure at
national conferences with “standing room only” crowds, or
the proliferation of radial training programs throughout the
United States, it is clear that the radial approach has come
into the national consciousness.
See page 36
Along with this tide of interest has come a slew of studies
examining various aspects of transradial procedures, includ-
ing the RIVAL (Radial Vs. Femoral Access for Coronary
Intervention) trial, the largest randomized trial ever con-
ducted comparing radial and femoral access in 7,021 pa-
tients with acute coronary syndrome undergoing coronary
angiography or intervention (2). Review of PubMed using
the search term “transradial” shows 159 articles between
2004 and 2007; the same search conducted between the
years 2008 and 2011 results in 391 articles. Aspects of radial
procedures long considered dogma have been challenged by
many of these studies and have taken the radial world of
“tips and tricks” into a new era of evidence-based medicine.
Compared with femoral access, radial access has consistently
been shown to be associated with lower resource use (3–5)
lower risk for vascular complications (2), and greater patient
satisfaction (2,4).
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as reported that he is a consultant to Terumo Medical.Despite this abundance of recent data, there are still many
unresolved issues; additional studies that refine radial tech-
nique, delineate advantages and disadvantages, and further
improve the safety of the procedure are welcome. In this
issue of JACC: Cardiovascular Interventions, Uhlemann et al.
(6) present data from the Leipzig Prospective Vascular
Ultrasound Registry in Radial Catheterization examining
the association between sheath size and radial arterial
complications. In their observational analysis of 455 pa-
tients, the rate of radial artery occlusion (RAO) with 6-F
sheaths was significantly higher than with 5-F sheaths.
They also treated patients with “symptomatic” RAO with a
short course of subcutaneous low molecular weight heparin
and found that there was a higher rate of recanalization
compared with patients who had “asymptomatic” RAO not
treated with anticoagulation. Finally, the investigators con-
clude that the rate of RAO in the registry is much higher
than previously reported.
The investigators should be congratulated for developing
a prospective registry and reporting their findings. But what
are the lessons that interventionalists can learn from this
study? Should the findings affect clinical care? Let us discuss
the major findings and put them into the context of what is
already known about RAO and its prevention. In the
Leipzig Registry, the rate of RAO ranged from 13.7% in
the 5-F sheath group to 30.5% in the 6-F sheath group. The
relationship between sheath size and RAO has been previ-
ously shown in a randomized trial (7), and the results by
Uhlemann et al. (6) confirm the randomized trial findings.
However, what is concerning about the findings from the
Leipzig Registry is that the rates of reported RAO are
substantially higher than previously reported (Fig. 1) (8–
3). Therapeutic approaches associated with a reduced risk
or RAO (“RAO-avoidance strategies”) are listed in Table 1.
RAO is a known risk of transradial catheterization, and the
use of RAO-avoidance strategies should be considered “best
practice.” In the study by Uhlemann et al. (6), 85.5% of the
patients did not undergo percutaneous coronary interven-
tion and thus received only 2,500 units of unfractionated
heparin. Given that the body mass index of the registry
patients was 25 kg/m2, thereby defining them as “over-
weight” or “obese,” this is a significant underdosing of
anticoagulation and clearly not enough to reduce the risk of
RAO. Two randomized trials have shown that maintaining
antegrade radial artery flow during radial artery compression—
so-called patent hemostasis—significantly reduces both early
and late RAO (11,12). The investigators do not report the
duration of radial artery compression and did not provide any
confirmation that patent hemostasis of the radial artery was
actually achieved. Thus, it appears that best practices to reduce
RAO were not followed in the registry, and the unacceptably
high rates of RAO in their study should be interpreted with
caution.
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45The second part of the study by Uhlemann et al. (6)
included the use of short-term anticoagulation for patients
with “symptomatic” RAO. These patients were treated with
either weight-adjusted or lower dose low molecular weight
heparin for a mean of 6 days, and the recanalization rate 9
days after catheterization was 31.5% compared with 5.4%
among patients not treated with low molecular weight
heparin. This is a strategy that has been previously described
(14), but it and the results from the Leipzig Registry raise
several questions: What are the symptoms of RAO? Were
the symptoms reported in the study due to RAO? More-
over, are the results of the study compelling enough to
recommend a short course of low molecular weight heparin
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Table 1. Strategies Associated With a Reduced Risk
Clearly Reduce Risk Lik
Anticoagulation* Enoxaparin†
Patent hemostasis Hydrophilic s
Sheath diameter  arterial diameter Routine use
Limiting the number of times the
same radial artery is accessed
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*Studied strategies includeunfractionatedheparin 70U/kgup to 5,000procedure. †Studied strategy includes enoxaparin 60 mg via the radial arteriafor patients with RAO? The conventional wisdom among
radial enthusiasts is that RAO is asymptomatic because of
collateral flow in the hand from the ulnar artery through an
intact palmar arch (among patients with normal Allen or
Barbeau tests). Although this is generally true, there is
plenty of evidence to suggest that not all RAO is clinically
silent. The radial artery supplies blood flow to the hand, and
RAO would be expected to result in hand ischemia manifest
as blanching or cyanosis of the first 3 fingers or entire hand,
ischemic ulceration, and hand pain (15). The patients in the
study by Uhlemann et al. (6) reported pain in the forearm
and thenar eminence, loss of handgrip strength, or pares-
thesias. There were no cases of critical limb ischemia. Based
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46on what is known about radial artery anatomy and RAO, it
is unlikely that these symptoms were solely due to RAO, but
instead they were more likely due to radial artery thrombosis
with overlying inflammation (arteritis) (16). In terms of the
treatment strategy, only symptomatic patients were treated
with anticoagulation, and all of them received therapy.
Thus, there was no true control group. In addition, al-
though no data are provided, it is highly probable that at
least a portion of these symptomatic patients were treated
with pain medications, some of which may have included
nonsteroidal anti-inflammatory agents. These, along with
corticosteroids, may be effective at treating the inflamma-
tion and pain. Whether they can increase radial artery
patency is unknown and should be evaluated in future
studies. Therefore, based on the results presented, it is
impossible to assess the efficacy of anticoagulation in pa-
tients with RAO and at best, these data should be inter-
preted as hypothesis-generating. Recent data suggest that
the use of ulnar compression increases the rate of radial
artery recanalization in patients with RAO (13) and such a
strategy may be more effective than anticoagulation at
establishing radial artery patency.
In the Leipzig Registry, all patients underwent post-
procedure ultrasound to assess for radial occlusion. How-
ever, pre-procedure ultrasound of the radial and ulnar
arteries as well as the antecubital fossa may provide valuable
information on arterial anatomy, such as diameter, tortuos-
ity, or presence of loops, which can help guide clinical
decision making regarding choice of right radial versus left
radial access and/or sheath/catheter size. For patients who
require large-bore guide catheters to accommodate large
devices, for simultaneous 2-stent techniques, or for patients
with smaller diameter radial arteries, sheathless techniques
could be used (17). However, it is important to note that
RAO is not eliminated when using sheathless guides; patent
hemostasis and adequate anticoagulation are still necessary (18).
Despite its marked safety advantage, cost-effectiveness,
nd potential mortality benefit in high-risk patients (19)
ompared with the femoral approach, the radial approach is
ot without limitations. RAO should be recognized as an
dverse consequence and routine assessment for post-
rocedure RAO should be an integral part of a catheteriza-
ion laboratory’s quality improvement program. The value
f studies such as the one by Uhlemann et al. (6) is in
eminding us that a cavalier attitude to management of the
adial access site is no longer acceptable. It is incumbent on
nterventionalists to reduce the risk for RAO. When RAO
oes occur, the first place to look is at our own practice.
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